stockrow
Saturday 7 November 2026
Export AURA’s income statement to Excel — free account
Aura Biosciences, Inc.
AURA Healthcare Biotechnology
- EPS
- −2.13%
- Free cash flow
- −56.3%
Quarter to June 2026, against a year earlier
6.56
0.22
+3.47%
Follow AURA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 5 | 5 | 34 | +163.0% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (24) | (22) | (35) | (59) | (76) | (87) | (106) | (131) | +27.9% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (24) | (22) | (35) | (59) | (76) | (87) | (106) | (131) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (1.03) | (82.06) | (8.95) | (1.96) | (1.93) | (1.75) | (1.76) | (1.75) | +9.3% | ||||||
| Cash flow | — | — | — | (0.71) | (66.27) | (6.28) | (1.82) | (1.61) | (1.61) | (1.40) | (1.09) | +12.1% | ||||||
| Capex | — | — | — | 0.00 | (2.10) | (0.41) | (0.04) | (0.02) | (0.03) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.71) | (68.37) | (6.69) | (1.86) | (1.63) | (1.63) | (1.41) | (1.09) | +12.2% | ||||||
| Book value | — | — | — | 1.05 | (296.22) | 29.52 | 6.53 | 5.70 | 3.06 | 2.27 | 3.32 | +13.7% | ||||||
| Shares, m | — | — | — | 29 | 0 | 5 | 30 | 40 | 50 | 60 | 72 | +12.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (21) | (24) | (32) | (55) | (64) | (80) | (85) | (103) | +26.5% | |||||
| Capex | — | — | — | (2) | (1) | (2) | (1) | (1) | (1) | 0 | 0 | (23.4%) | ||||||
| Free cash flow | — | — | — | (21) | (25) | (35) | (56) | (65) | (81) | (85) | (103) | +26.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 27 | 16 | 146 | 186 | 219 | 146 | 131 | 309 | +30.0% | |||||
| Net debt | — | — | — | (32) | (17) | (149) | (189) | (226) | (151) | (144) | (324) | +28.2% | ||||||
| Shareholders’ equity | — | — | — | 31 | (109) | 152 | 196 | 226 | 152 | 137 | 315 | +28.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (163.16) | (101.87) | (50.72) | (30.61) | (31.90) | (39.73) | (60.35) | (47.42) | +102.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (682.29) | (558.12) | 0.00 | (6,857.59) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 30.83 | 30.73 | (211.88) | (33.78) | (36.26) | (46.01) | (73.52) | (53.49) | (104.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 42 | 52 | 72 | 89 | 109 | 113 | — | +21.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Aura Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | $695.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ATTO Attovia Therapeutics, Inc. | $684.8M | — | — | — | n/m | — | 100.00% | (4,845.11%) | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $670.7M | — (loss-making) | — (loss-making) | −59.37% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| SLDB Solid Biosciences Inc. | $662.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | |
| ACHV Achieve Life Sciences, Inc. | $656.0M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SGMT Sagimet Biosciences Inc. | $641.5M | — (loss-making) | — (loss-making) | — | n/m | −21.95% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| WVE WAVE Life Sciences Ltd. | $635.1M | — (loss-making) | — (loss-making) | +72.95% (above 0%: growing) | n/m | −33.94% (below 0%: shrinking) | 100.00% | (501.95%) | Compare |
| ZVRA Zevra Therapeutics, Inc. | $626.6M | 9.0× | 9.2× | +44.86% (above 0%: growing) | n/m | +106.77% (above 0%: growing) | 95.25% | 30.67% | Compare |
| Median of peers | $659.3M | — | — | +44.86% | — | −19.01% | 97.63% | 0.00% |
Pay and ownership Proxy statement filed 29 June 2026
Ownership
Directors and executive officers, together
1.90%
Entities affiliated with TCG Crossover
9.99%
Adage Capital Partners, L.P.
8.70%
Entities affiliated with Frazier
6.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement